EZH2 and neoplasm: In the context of bone metastasis, EZH2 promotes osteolytic lesion development by upregulating integrin β1 and activating FAK–TGF-β signaling, thus enhancing osteoclast differentiation and tumor growth within the skeletal niche [197].